Transcriptomic analysis identifies CYP27A1 as a diagnostic marker for the prognosis and immunity in lung adenocarcinoma.

IF 2.9 4区医学 Q3 IMMUNOLOGY

BMC Immunology Pub Date : 2023-10-10 DOI:10.1186/s12865-023-00572-1

Yi Yin, Muqun He, Yunjian Huang, Xianhe Xie

{"title":"Transcriptomic analysis identifies CYP27A1 as a diagnostic marker for the prognosis and immunity in lung adenocarcinoma.","authors":"Yi Yin, Muqun He, Yunjian Huang, Xianhe Xie","doi":"10.1186/s12865-023-00572-1","DOIUrl":null,"url":null,"abstract":"Background: The association between lipid metabolism disorder and carcinogenesis is well-established, but there is limited research on the connection between lipid metabolism-related genes (LRGs) and lung adenocarcinoma (LUAD). The objective of our research was to identify LRGs as the potential biomarkers for prognosis and assess their impact on immune cell infiltration in LUAD.Methods: We identified novel prognostic LRGs for LUAD patients via the bioinformatics analysis. CYP27A1 expression level was systematically evaluated via various databases, such as TCGA, UALCAN, and TIMER. Subsequently, LinkedOmics was utilized to perform the CYP27A1 co-expression network and GSEA. ssGSEA was conducted to assess the association between infiltration of immune cells and CYP27A1 expression. CYP27A1's expression level was validated by qRT-PCR analysis.Results: CYP27A1 expression was decreased in LUAD. Reduced CYP27A1 expression was linked to unfavorable prognosis in LUAD. Univariate and multivariate analyses indicated that CYP27A1 was an independent prognostic biomarker for LUAD patients. GSEA results revealed a positive correlation between CYP27A1 expression and immune-related pathways. Furthermore, CYP27A1 expression was positively correlated with the infiltration levels of most immune cells.Conclusion: CYP27A1 is a potential biomarker for LUAD patients, and our findings provided a novel perspective to develop the prognostic marker for LUAD patients.","PeriodicalId":9040,"journal":{"name":"BMC Immunology","volume":"24 1","pages":"37"},"PeriodicalIF":2.9000,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565965/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12865-023-00572-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Background: The association between lipid metabolism disorder and carcinogenesis is well-established, but there is limited research on the connection between lipid metabolism-related genes (LRGs) and lung adenocarcinoma (LUAD). The objective of our research was to identify LRGs as the potential biomarkers for prognosis and assess their impact on immune cell infiltration in LUAD.

Methods: We identified novel prognostic LRGs for LUAD patients via the bioinformatics analysis. CYP27A1 expression level was systematically evaluated via various databases, such as TCGA, UALCAN, and TIMER. Subsequently, LinkedOmics was utilized to perform the CYP27A1 co-expression network and GSEA. ssGSEA was conducted to assess the association between infiltration of immune cells and CYP27A1 expression. CYP27A1's expression level was validated by qRT-PCR analysis.

Results: CYP27A1 expression was decreased in LUAD. Reduced CYP27A1 expression was linked to unfavorable prognosis in LUAD. Univariate and multivariate analyses indicated that CYP27A1 was an independent prognostic biomarker for LUAD patients. GSEA results revealed a positive correlation between CYP27A1 expression and immune-related pathways. Furthermore, CYP27A1 expression was positively correlated with the infiltration levels of most immune cells.

Conclusion: CYP27A1 is a potential biomarker for LUAD patients, and our findings provided a novel perspective to develop the prognostic marker for LUAD patients.

Abstract Image

查看原文本刊更多论文

转录组学分析确定CYP27A1是肺腺癌预后和免疫的诊断标志物。

背景：脂质代谢紊乱与致癌作用之间的联系已经得到证实，但对脂质代谢相关基因（LRGs）与肺腺癌（LUAD）之间的联系的研究有限。我们的研究目的是确定LRG作为潜在的预后生物标志物，并评估其对LUAD免疫细胞浸润的影响。方法：通过生物信息学分析，我们为LUAD患者确定了新的预后LRG。CYP27A1的表达水平通过各种数据库进行系统评估，如TCGA、UALCAN和TIMER。随后，利用LinkedOmics进行CYP27A1共表达网络和GSEA。进行ssGSEA以评估免疫细胞浸润与CYP27A1表达之间的相关性。通过qRT-PCR分析验证CYP27A1的表达水平。结果：CYP27A1在LUAD中的表达降低。CYP27A1表达降低与LUAD的不良预后有关。单变量和多变量分析表明CYP27A1是LUAD患者的独立预后生物标志物。GSEA结果显示CYP27A1的表达与免疫相关途径呈正相关。此外，CYP27A1的表达与大多数免疫细胞的浸润水平呈正相关。结论：CYP27A1是LUAD患者潜在的生物标志物，我们的研究结果为开发LUAD患者的预后标志物提供了新的视角。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Immunology 医学-免疫学

CiteScore

5.50

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： BMC Immunology is an open access journal publishing original peer-reviewed research articles in molecular, cellular, tissue-level, organismal, functional, and developmental aspects of the immune system as well as clinical studies and animal models of human diseases.